Core Laboratories
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Core Laboratories's revenues will grow 7.9% and EPS will grow 12.9%.
The average estimate for revenue is $266.4 million. On the bottom line, the average EPS estimate is $1.31.
Revenue details
Last quarter, Core Laboratories notched revenue of $260.9 million. GAAP reported sales were 11% higher than the prior-year quarter's $234.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at $1.22. GAAP EPS of $1.22 for Q1 were 8.0% higher than the prior-year quarter's $1.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 37.3%, 100 basis points better than the prior-year quarter. Operating margin was 30.3%, 70 basis points better than the prior-year quarter. Net margin was 21.7%, 130 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $1.08 billion. The average EPS estimate is $5.26.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 657 members out of 670 rating the stock outperform, and 13 members rating it underperform. Among 145 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 145 give Core Laboratories a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is outperform, with an average price target of $128.79.
Is Core Laboratories the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add Core Laboratories to My Watchlist.
